List of Excipients in Branded Drug DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC SOLUTION

Generic Drugs Containing DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC SOLUTION

Company	Ingredient	NDC	Excipient
Micro Labs Limited	dorzolamide hydrochloride	42571-141	BENZALKONIUM CHLORIDE
Micro Labs Limited	dorzolamide hydrochloride	42571-141	HYDROXYETHYL CELLULOSE
Micro Labs Limited	dorzolamide hydrochloride	42571-141	MANNITOL
Micro Labs Limited	dorzolamide hydrochloride	42571-141	SODIUM HYDROXIDE
Micro Labs Limited	dorzolamide hydrochloride	42571-141	TRISODIUM CITRATE DIHYDRATE
Micro Labs Limited	dorzolamide hydrochloride	42571-141	WATER

What are the Most Frequently-Used Excipients in DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC SOLUTION?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	HYDROXYETHYL CELLULOSE
1	MANNITOL
1	SODIUM HYDROXIDE
1	TRISODIUM CITRATE DIHYDRATE
1	WATER

Dorzolamide Hydrochloride Ophthalmic Solution: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 4, 2026

Dorzolamide hydrochloride ophthalmic solution is a mature, genericized carbonic anhydrase inhibitor used to reduce elevated intraocular pressure in glaucoma and ocular hypertension. The core active ingredient and conventional preserved formulation have limited exclusivity value. Commercial opportunity is concentrated in preservative-free delivery, multidose packaging, improved tolerability, differentiated viscosity and retention, combination products, and manufacturing efficiency.

The standard 2% formulation contains dorzolamide hydrochloride in an aqueous buffered vehicle with hydroxyethyl cellulose, mannitol, sodium citrate, sodium hydroxide, and benzalkonium chloride, depending on the product and market. The principal technical challenge is balancing chemical stability, ocular comfort, microbial protection, container compatibility, and dose reproducibility.[1]

What is dorzolamide hydrochloride ophthalmic solution?

Dorzolamide hydrochloride ophthalmic solution is a topical ocular carbonic anhydrase inhibitor. It is administered as a 2% solution for the treatment of elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension.

Attribute	Product profile
Active ingredient	Dorzolamide hydrochloride
Strength	2% ophthalmic solution, equivalent to 20 mg/mL dorzolamide
Drug class	Topical carbonic anhydrase inhibitor
Original branded product	Trusopt
Original sponsor	Merck
Typical dosing	One drop three times daily as monotherapy; twice daily when used with a beta blocker
Route	Topical ophthalmic
Dosage form	Sterile aqueous solution
Primary indications	Ocular hypertension and open-angle glaucoma
Combination product	Dorzolamide hydrochloride/timolol maleate ophthalmic solution
FDA regulatory pathway for generics	Abbreviated New Drug Application, or ANDA

Dorzolamide reduces aqueous humor production by inhibiting carbonic anhydrase in the ciliary processes. Its commercial value is linked to chronic use, refill frequency, and the need for long-term tolerability rather than to acute treatment demand.[1]

What excipients are used in dorzolamide hydrochloride ophthalmic solution?

The conventional formulation uses excipients for pH control, tonicity, viscosity, chemical stability, and preservation. The Trusopt label identifies hydroxyethyl cellulose, mannitol, sodium citrate, sodium hydroxide, benzalkonium chloride, and purified water as formulation components.[1]

Excipient	Primary function	Commercial and technical considerations
Hydroxyethyl cellulose	Viscosity modifier and retention aid	Can increase ocular residence time but may affect drop size, clarity, and blinking comfort
Mannitol	Tonicity adjustment and stabilizing polyol	Generally well established in ophthalmic products; concentration affects osmolality
Sodium citrate	Buffering agent	Supports pH control and may influence comfort and chemical stability
Sodium hydroxide	pH adjustment	Used to establish the target formulation pH
Benzalkonium chloride	Antimicrobial preservative	Effective and inexpensive, but associated with ocular-surface tolerability concerns during chronic use
Purified water	Vehicle	Must meet sterile ophthalmic manufacturing requirements

The formulation has a relatively acidic pH compared with the normal tear film. This can contribute to transient stinging. The active ingredient itself also has a bitter taste and can cause ocular discomfort if drainage through the nasolacrimal system produces systemic exposure.[1]

Why does hydroxyethyl cellulose matter?

Hydroxyethyl cellulose is more than a passive thickener. It influences:

• Drop retention on the ocular surface
• Elimination rate through blinking and drainage
• Drop volume and delivery reproducibility
• Patient perception of viscosity
• Solution clarity
• Filterability and filling performance
• Compatibility with preservative systems

A higher-viscosity formulation may improve retention, but excessive viscosity can impair administration, increase blurred vision, and create variability in delivered volume. The strongest development approach is usually a controlled viscosity range rather than maximum viscosity.

Why is benzalkonium chloride commercially important?

Benzalkonium chloride is a conventional preservative in multidose ophthalmic products. It enables repeated use from a multidose bottle and reduces microbial-growth risk after opening. Its limitation is chronic ocular-surface exposure. Preservative-related irritation is commercially relevant in glaucoma because patients may use several topical products for years.

A preservative-free product can therefore be differentiated without changing the active ingredient. The differentiation is strongest among patients with ocular-surface disease, contact-lens-related intolerance, chronic polypharmacy, or poor adherence caused by burning and irritation.

What formulation patents protect dorzolamide ophthalmic solution?

The original active-ingredient and branded-product patent estate is largely historical. Trusopt was approved by the FDA in 1994, and the conventional dorzolamide product has been genericized for many years.[1,2]

The principal patent opportunities now relate to formulation and delivery rather than basic composition of matter. Potentially protectable subject matter includes:

1. Preservative-free dorzolamide solutions.
2. Multidose preservative-free containers.
3. Specific pH and buffer systems.
4. Viscosity-controlled formulations.
5. Low-irritation excipient combinations.
6. Container-closure systems that limit microbial ingress.
7. Unit-dose packaging and stability profiles.
8. Dorzolamide combinations with timolol or other glaucoma agents.
9. Manufacturing processes that improve impurity control or batch uniformity.
10. Formulations designed to reduce drop size or improve ocular residence.

A formulation patent must do more than substitute one conventional ophthalmic excipient for another. For strong protection, the sponsor generally needs a defined technical effect, such as improved stability, reduced preservative exposure, reduced irritation, improved container integrity, or a clinically meaningful dosing advantage.

When does dorzolamide lose exclusivity?

Dorzolamide hydrochloride has already lost its principal small-molecule exclusivity. The original Trusopt product is no longer protected by a commercially meaningful composition-of-matter monopoly in the United States.

Exclusivity category	Status
New chemical entity exclusivity	Expired
Original branded product exclusivity	Expired
Conventional dorzolamide solution market	Generic competition
Biosimilar exclusivity	Not applicable
Current commercial protection	Product-specific formulation, device, manufacturing, trademark, and market-access advantages
Relevant regulatory route	ANDA for therapeutically equivalent generic products

The current opportunity is not recovery of the original active-ingredient exclusivity. It is the creation of differentiated products that may qualify for separate patent protection or command a premium through tolerability, packaging, adherence, or supply reliability.

What is the Orange Book status of dorzolamide ophthalmic solution?

Dorzolamide ophthalmic solution is an FDA-approved small-molecule drug subject to the ANDA framework. FDA Orange Book listings historically identify the reference listed drug and approved generic equivalents for dorzolamide ophthalmic solution and dorzolamide/timolol ophthalmic solution.[2]

An Orange Book listing does not itself establish that a product has durable commercial protection. For a generic applicant, the key issues are:

• Whether the reference product has listed patents.
• Whether any listed patents remain unexpired.
• Whether the applicant must make a Paragraph IV certification.
• Whether the product has any unexpired reference-product exclusivity.
• Whether formulation or device claims create a separate patent barrier.

Because conventional dorzolamide solution is mature, an ANDA applicant will usually face a lower patent barrier than an applicant targeting a newly patented preservative-free or device-enabled formulation.

Are there Paragraph IV challenges for dorzolamide ophthalmic solution?

Paragraph IV risk is primarily relevant when an ANDA applicant challenges an unexpired patent listed for the reference product. For the conventional dorzolamide solution market, the principal original patents are expired, so routine generic entry generally does not depend on defeating a live composition-of-matter patent.

Paragraph IV exposure can arise in three situations:

• A newer formulation patent is listed for a branded or authorized-generic product.
• A preservative-free or multidose product has patented container technology.
• A combination product has unexpired method-of-use or formulation claims.

A generic applicant targeting a differentiated formulation must conduct a separate patent review. It cannot assume that the expiration of the original Trusopt estate eliminates all risk around a later-developed product.

What patent litigation affects dorzolamide products?

The main historic litigation risk involved the original branded product, formulation claims, and generic entry following FDA approval of ANDAs. The commercially important litigation phase has passed for conventional dorzolamide solution.

Current litigation exposure is more likely to involve:

• Product-specific formulation patents.
• Device and container patents.
• Trade dress and trademark rights.
• Manufacturing process patents.
• Combination products containing dorzolamide and timolol.
• Allegations involving ANDA labeling or method-of-use carve-outs.

No biosimilar litigation framework applies because dorzolamide hydrochloride is a chemically synthesized small molecule, not a biologic. The relevant competitors are generic manufacturers, not biosimilar sponsors.

What excipient strategies create commercial opportunity?

Preservative-free unit-dose solution

The most straightforward opportunity is a preservative-free unit-dose product. It can target patients who experience ocular-surface irritation or who use several chronic glaucoma medications.

Advantages include:

• Removal of benzalkonium chloride.
• Clear tolerability positioning.
• Simple regulatory logic if the formulation is otherwise close to the reference product.
• Lower dependence on preservative compatibility.

Limitations include higher packaging cost, greater logistics burden, more waste, and weaker convenience for patients who prefer a multidose bottle.

Unit-dose products need strong control of fill volume, container extractables, sterility assurance, and opening behavior. Plastic selection can affect sorption, leachables, oxygen transmission, and product loss.

Preservative-free multidose delivery

A preservative-free multidose bottle can deliver a stronger commercial proposition than unit-dose packaging because it combines tolerability with convenience. The container must control microbial ingress after repeated actuation.

Potentially differentiating technologies include:

• One-way valves.
• Filtered air-return systems.
• Non-return dispensing pumps.
• Collapsible containers.
• Tip designs that reduce contamination.
• Metered-dose delivery.

The device may create a separate patent estate, but regulatory risk is higher because the sponsor must demonstrate container performance, microbial robustness, dose uniformity, extractables and leachables, and shelf-life stability.

Low-irritation buffered formulation

A formulation can be designed around improved ocular comfort through changes in:

• Buffer species and concentration.
• pH.
• Ionic strength.
• Preservative concentration.
• Viscosity.
• Osmolality.
• Surface-active components.

The commercial challenge is that pH and osmolality changes can affect solubility, chemical degradation, comfort, and comparability. The best opportunity is not a nominally different buffer. It is a formulation with documented reduction in stinging, redness, or ocular-surface disturbance.

Viscosity-enhanced formulation

A modest viscosity increase can improve ocular residence time and potentially support twice-daily use or reduced drainage. The product must preserve:

• Clear appearance.
• Drop-size consistency.
• Easy dispensing.
• Rapid visual recovery.
• Compatibility with the bottle and tip.
• Acceptable sterile filtration and filling.

A viscosity claim is more defensible when linked to a defined rheological profile and a demonstrated performance benefit.

Combination products

Dorzolamide/timolol ophthalmic solution is an established combination category. Combination products can reduce the number of daily administrations and improve regimen simplicity.

Commercial barriers include:

• Separate active-ingredient stability.
• Preservative compatibility.
• pH optimization for both actives.
• Larger impurity profile.
• Dose uniformity for two active ingredients.
• More complex bioequivalence and labeling requirements.

The combination market is more commercially defensible than single-agent dorzolamide when the product reduces administration burden or provides a preservative-free alternative.

How does dorzolamide compare with competing glaucoma products?

Product category	Competitive advantage	Excipient opportunity	Main weakness
Dorzolamide 2% solution	Established efficacy and generic availability	Preservative-free, low-irritation, improved delivery	Frequent dosing and stinging
Dorzolamide/timolol combination	Fewer bottles and fewer administrations	Preservative-free combination and multidose delivery	More complex stability profile
Brimonidine products	Broad glaucoma use and multiple formulations	Preservative-free or low-concentration preservative systems	Allergy and ocular-surface intolerance
Prostaglandin analogs	Often once-daily dosing	Vehicle and preservative optimization	Iris pigmentation, eyelash effects, hyperemia
Brinzolamide suspension	Carbonic anhydrase inhibitor alternative	Suspension uniformity and settling control	Shake requirements and visual blurring
Timolol solution or gel	Low-cost beta blocker therapy	Gel-forming and preservative-free systems	Cardiopulmonary contraindications

Dorzolamide’s principal weakness is dosing frequency. Its principal formulation advantage is that it is an aqueous solution rather than a suspension, simplifying dose uniformity and administration relative to brinzolamide suspension.

What FDA regulatory issues affect a new dorzolamide formulation?

A conventional generic solution may pursue an ANDA if it meets pharmaceutical equivalence and bioequivalence requirements. A materially differentiated formulation or delivery system may require a more complex regulatory strategy, depending on the extent of formulation and device changes.

The development program should address:

• Sterility and sterility assurance.
• Particulate matter.
• Visible and subvisible particles.
• pH and osmolality.
• Assay and degradation products.
• Preservative content and effectiveness, where applicable.
• Container-closure integrity.
• Extractables and leachables.
• Drop size and delivered volume.
• Microbial ingress for multidose systems.
• In-use stability.
• Ocular irritation and tolerability.
• Comparative clinical performance where required.

FDA ophthalmic guidance emphasizes product quality attributes that are especially important for sterile topical products, including container performance, microbial control, and formulation characterization.[3]

What manufacturing and intellectual-property barriers matter?

The active ingredient is not the primary barrier. Manufacturing differentiation can arise from:

• Control of hydrochloride salt purity.
• Low-level impurity management.
• Prevention of oxidative or hydrolytic degradation.
• Sterile filtration and aseptic filling.
• Compatibility with low-volume unit-dose containers.
• Consistent bottle actuation force.
• Accurate drop-volume control.
• Device assembly and component inspection.

A commercially useful patent estate should combine formulation claims with process and packaging claims. A single narrow excipient claim is vulnerable to design-around. A layered estate can cover the composition, pH range, viscosity range, container, dispensing mechanism, and manufacturing controls.

Geographic coverage should prioritize the United States, European Union, Japan, Canada, Australia, Brazil, and major emerging glaucoma markets. Patent term, regulatory filing strategy, and Orange Book eligibility differ by jurisdiction. A U.S. formulation patent may have little value if the principal growth market is outside the United States and local patent filings were not made within the applicable priority period.

Which companies are challenging the dorzolamide market?

The conventional market is supplied by generic manufacturers rather than by a single dominant challenger. Competition typically centers on:

• Product price.
• Pharmacy substitution.
• Supply continuity.
• Bottle and cap design.
• Preservative-free availability.
• Combination-product breadth.
• Contract manufacturing capacity.

Potential commercial participants include established generic ophthalmic manufacturers, specialty ophthalmology companies, branded-generic firms, and device companies with preservative-free multidose platforms. The strongest commercial position is likely to come from a sponsor that controls both the sterile fill-finish operation and the delivery device.

What is the revenue exposure and commercial outlook?

Revenue exposure for conventional dorzolamide solution is generally limited by generic pricing and substitution. The higher-value segments are:

1. Preservative-free products.
2. Combination products.
3. Premium multidose delivery systems.
4. Markets with limited generic supply.
5. Institutional and hospital channels that value supply reliability.
6. Products aimed at ocular-surface disease and polypharmacy patients.

The commercial case should be based on net price, refill persistence, market share, and manufacturing cost rather than on the historic sales of Trusopt. Premium pricing requires a measurable benefit, such as better tolerability, lower dosing burden, lower wastage, or improved availability.

What generic launch scenarios exist?

Scenario	Product profile	Market impact
Low-cost conventional generic	Preserved 2% solution in standard bottle	Highest price pressure
Preservative-free unit dose	Single-use sterile containers	Premium niche with higher packaging cost
Preservative-free multidose	Specialized contamination-control bottle	Strongest differentiation if convenience is maintained
Dorzolamide/timolol generic	Fixed-dose combination	Competes on regimen simplification
Improved-viscosity solution	Residence-time or dosing-performance positioning	Requires technical and clinical support
Authorized generic	Branded-equivalent product under alternative commercialization	Can reduce price volatility and expand distribution

The most credible launch strategy is a conventional ANDA product for baseline volume combined with a differentiated preservative-free or device-enabled product for margin protection.

Key Takeaways

• Dorzolamide hydrochloride ophthalmic solution is a mature small-molecule product with expired core exclusivity.
• The conventional formulation uses hydroxyethyl cellulose, mannitol, sodium citrate, sodium hydroxide, benzalkonium chloride, and water.
• Benzalkonium chloride removal is the clearest excipient-led differentiation strategy.
• Preservative-free multidose packaging offers greater commercial value than unit-dose packaging but creates higher device and regulatory complexity.
• Hydroxyethyl cellulose can support viscosity and ocular retention, but excessive viscosity may reduce comfort and dosing consistency.
• Current patent value is more likely to arise from formulation, container, device, manufacturing, and method-of-use claims than from the active ingredient.
• Dorzolamide is not subject to biosimilar competition.
• Conventional generic entry is primarily an ANDA and pricing issue, while differentiated products may create new patent and regulatory barriers.
• The strongest commercial platform combines a low-cost generic solution with a preservative-free, patient-tolerable delivery system.
• Combination products containing dorzolamide and timolol can provide greater regimen value than single-agent dorzolamide.

FAQs

Is dorzolamide hydrochloride ophthalmic solution preservative-free?

Some products are preserved with benzalkonium chloride, while other products may use preservative-free unit-dose or specialized multidose packaging. The specific excipient profile must be confirmed from the product labeling.

Can benzalkonium chloride be removed without changing the dorzolamide formulation?

It can be removed, but the product then requires a packaging and sterility strategy that protects against microbial contamination during repeated use. A unit-dose format is simpler than a preservative-free multidose bottle.

Is dorzolamide ophthalmic solution a biologic?

No. Dorzolamide hydrochloride is a chemically synthesized small molecule. Generic products generally use the ANDA pathway rather than the biosimilar pathway.

Does a new excipient automatically create patent protection?

No. A patentable formulation generally requires a novel and nonobvious combination, defined technical parameters, and evidence of a meaningful performance benefit. Routine substitution of one conventional ophthalmic excipient may be vulnerable to obviousness and design-around challenges.

Which product has stronger commercial differentiation: dorzolamide solution or brinzolamide suspension?

Dorzolamide solution has simpler dose uniformity and administration because it does not require shaking as a suspension. Brinzolamide may offer a different tolerability and formulation profile, but its suspension characteristics create separate manufacturing and patient-use requirements.

References

1. U.S. Food and Drug Administration. (1994). TRUSOPT (dorzolamide hydrochloride ophthalmic solution) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2023). Quality considerations for ophthalmic drug products: Guidance for industry. https://www.fda.gov/

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Ophthalmic preparations and preservative effectiveness standards. U.S. Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2022). Container closure systems for packaging human drugs and biologics: Guidance for industry. https://www.fda.gov/